Ventana Medical Systems
David Tast has a diverse work experience in the field of medical and life sciences. David has held various managerial and leadership positions in reputable companies. David began their career at Children's Hospital Los Angeles as a Graduate Student and then worked as a Field Applications Scientist at Promega, where they excelled in driving sales and building strong customer relationships. David later joined Corning as a Sr. Scientific Applications Manager, leading a national team in sales and business development for genomics and drug discovery products. David then worked at LION Bioscience as a Scientific Consultant, providing technical support and managing projects for professional services. Following that, David worked at Ventana Medical Systems as a Director of Strategic Marketing and later as the Director of Product Technical Support. David moved to Roche Tissue Diagnostics at F. Hoffmann-La Roche AG as a Senior Manager of Product Technical Support. Overall, their experience encompasses strategic marketing, product development, technical support, and sales.
David Tast earned their Bachelors of Science degree in Biochemistry from California State University, Long Beach, from 1983 to 1987. Later, they attended the University of Southern California, where they completed their PhD in Pathobiology from 1994 to 1999.
Ventana Medical Systems
Ventana Medical Systems, Inc., a member of the Roche Group, innovates and manufactures instruments and reagents that automate tissue processing and slide staining for cancer diagnostics. VENTANA solutions are used in clinical histology and drug development research laboratories worldwide. The company’s intuitive, integrated staining and workflow management platforms that optimize laboratory efficiencies to reduce errors – support diagnosis and inform treatment decisions for anatomic pathology professionals. Together with Roche, Ventana is driving personalized healthcare through accelerated drug discovery and the development of “companion diagnostics” to identify the patients most likely to respond favorably to specific therapies. Visit www.ventana.com to learn more.